Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ).
Qyuns Therapeutics Co., Ltd. has announced successful Phase III clinical trial results for Crusekitug (QX002N), a treatment for ankylosing spondylitis, presented at the 2025 ACR Annual Meeting. The trial demonstrated significant improvements in clinical symptoms and spinal function, with Crusekitug showing a higher ASAS40 response rate compared to placebo, and favorable safety outcomes. These results position Crusekitug as a promising new treatment option, with the company planning to expedite its registration and market launch.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$24.50 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative therapies for autoimmune diseases. The company’s primary product, Crusekitug (QX002N), is a monoclonal antibody targeting IL-17A, designed to treat conditions such as ankylosing spondylitis by inhibiting inflammation pathways.
Average Trading Volume: 926,375
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.4B
See more insights into 2509 stock on TipRanks’ Stock Analysis page.